Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
257
datasets available to search
ShareScore release 0.9.0
Dataset results
257 results for “pulmonary exacerbations”
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
ClinicalTrials.gov study NCT00076089. IPD Sharing: Not stated. Countries: 6. Publications: 2.
Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT01353235. IPD Sharing: NO. Countries: 1. Publications: 2.
Data from: Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients
Open the record for dataset details and reuse information.
Effectiveness of steroid therapy on pneumonic chronic obstructive pulmonary disease exacerbation: a multi-centred retrospective cohort study
Open the record for dataset details and reuse information.
CARE-CF-1 Clinical trial data: An exploratory, randomized, double-blind, placebo-controlled 6-arm clinical trial examining cysteamine as an adjunct therapy for the treatment of pulmonary exacerbations of cystic fibrosis
<p><em>Background:</em> Emerging data suggests a possible role for cysteamine as an adjunct treatment for pulmonary exacerbations of cystic fibrosis (CF) that continue to be a major clinical challenge. There are no studies investigating the use of cysteamine in pulmonary exacerbations of CF. This exploratory randomized clinical trial was conducted to answer the question: In future pivotal trials of cysteamine as an adjunct treatment in pulmonary exacerbations of CF, which candidate cysteamine dosing regimens should be tested and which are the most appropriate, clinically meaningful outcome measures to employ as endpoints?</p> <p><em>Methods and findings: </em>Multicentre double-blind randomized clinical trial. Adults experiencing a pulmonary exacerbation of CF being treated with standard care that included aminoglycoside therapy were randomized equally to a concomitant 14-day course of placebo, or one of 5 dosing regimens of cysteamine. Outcomes were recorded on days 0, 7, 14 and 21 and included sputum bacterial load and the patient reported outcome measures (PROMs): Chronic Respiratory Infection Symptom Score (CRISS), the Cystic Fibrosis Questionnaire–Revised (CFQ-R); FEV1, blood leukocyte count, and inflammatory markers. Eighty nine participants in fifteen US and EU centres were randomized, 78 completed the 14-day treatment period. Cysteamine had no significant effect on sputum bacterial load, however technical difficulties limited interpretation. The most consistent findings were for cysteamine 450mg twice daily that had effects additional to that observed with placebo, with improved symptoms, CRISS additional 9.85 points (95% CI 0.02, 19.7) p=0.05, reduced blood leukocyte count by 2.46x109 /l (95% CI 0.11, 4.80), p=0.041 and reduced CRP by geometric mean 2.57 nmol/l (95% CI 0.15, 0.99), p=0.049.</p> <p><em>Conclusion:</em> In this exploratory study cysteamine appeared to be safe and well-tolerated. Future pivotal trials investigating the utility of cysteamine in pulmonary exacerbations of CF need to include the cysteamine 450mg doses and CRISS and blood leukocyte count as outcome measures.</p>
Data from: Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis
Objective: Limited data exist concerning the role of inhaled hypertonic saline (HS) in decreasing pulmonary exacerbations in cystic fibrosis (CF), especially as more advanced stages of CF lung disease were excluded in prior studies. Herein we retrospectively determined the efficacy of inhaled HS in reducing CF pulmonary exacerbations when stratified according to the severity of CF lung disease. Stratification was based on the framework of the Pulmonary Therapeutics Committee's published gradation of obstructive lung physiology in CF, i.e., mild (FEV1 > 70%), moderate (FEV1 40-70%) and severe (FEV1 < 40%) lung disease, respectively. Design: A retrospective review of the Port CF® database over a 3-year period performed at an academic CF care center. Results: 340 pulmonary exacerbations were identified; inhaled HS was being used in 99 of these cases. Univariate analysis demonstrated a significant reduction in pulmonary exacerbations only in mild obstruction (OR=0.09, CI 0.01-0.81, p=0.012); however, multivariate logistic regression that adjusted for confounding variables showed a reduction in pulmonary exacerbations across the entire spectrum of obstructive lung disease when using inhaled HS i.e., mild obstructive CF lung disease (OR=0.17, CI 0.05-0.58, p=0.004), moderate obstructive CF lung disease (OR=0.39, CI 0.16-0.93, p=0.034), as well as severe obstructive CF lung disease (OR=0.02, CI 0.001-0.45, p=0.015). Moreover, inhaled HS appeared reasonably well tolerated across all stages of lung disease severity, and was discontinued in only 7% of cases (n=4) with severe lung disease. Conclusion: In this study, inhaled HS appeared to reduce pulmonary exacerbations in CF lung disease at all stages of obstruction. This underscores the importance of therapeutic inhaled HS in CF lung disease, regardless of severity of lung obstruction.
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT02700919. IPD Sharing: NO. Countries: 10. Publications: 0.
Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacerbation.
ClinicalTrials.gov study NCT06445686. IPD Sharing: NO. Countries: 1. Publications: 0.
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
ClinicalTrials.gov study NCT00181207. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
ClinicalTrials.gov study NCT00381628. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Location and Timing of Inhaler Use, Exacerbations and Physical Activity in Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT02661321. IPD Sharing: NO. Countries: 0. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT05400369. IPD Sharing: YES. Countries: 1. Publications: 0.
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT02299375. IPD Sharing: YES. Countries: 8. Publications: 0.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study
ClinicalTrials.gov study NCT02657525. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.
Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
ClinicalTrials.gov study NCT00791505. IPD Sharing: Not stated. Countries: 0. Publications: 1.
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
ClinicalTrials.gov study NCT02918409. IPD Sharing: NO. Countries: 1. Publications: 0.
Performance of Novel Bed Side Scores as Predictors of Hospital Outcome in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Among Women; Cohort Study
ClinicalTrials.gov study NCT05370664. IPD Sharing: Not stated. Countries: 0. Publications: 6.
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT04682899. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
ClinicalTrials.gov study NCT07112235. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Nutritional Status in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT03709498. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.